 |
|
|
|
 |
|
|
| Article 1 to 10 out of 31 concerning AstraZeneca PLC
|
-
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
(21 Jan 2010)
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia ...
-
Novexel to be acquired by AstraZeneca
(04 Jan 2010)
Novexel announced that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company ...
-
Biovitrum Sells Obesity Program to AstraZeneca
(23 Dec 2009)
Biovitrum AB announced that AstraZeneca has acquired all of Biovitrum’s rights to its leptin modulator program aimed at treating obesity. Biovitrum will receive from AstraZeneca an upfront payment of Euro 6M and milestone payments contingent on ...
-
AstraZeneca and Targacept: Global Collaboration and License Agreement for TC-5214 for the Treatment of Major Depressive Disorder
(07 Dec 2009)
AstraZeneca and Targacept, Inc. announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently ...
-
UCB and AstraZeneca form alliance for the commercialization of Cimzia in Brazil
(29 Sep 2009)
UCB and AstraZeneca announced that they have entered into a partnership to register and commercialize UCB's PEGylated anti-TNF alpha drug Cimzia® (certolizumab pegol) in Brazil. The drug is to be registered for the treatment of rheumatoid arthritis ...
-
AstraZeneca Canada Inc. expands product portfolio to include vaccines
(20 Aug 2009)
AstraZeneca Canada Inc. announced that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada. Working in partnership with its biologics subsidiary MedImmune, AstraZeneca Canada ...
-
Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement
(17 Jun 2009)
Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications. ...
-
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
(25 Mar 2009)
BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications. BioDuro will provide integrated research services in the areas of discovery ...
-
Ken Powell To Leave Arrow Therapeutics
(21 Jan 2009)
Antiviral company Arrow Therapeutics, a fully-owned subsidiary of AstraZeneca (AZ), announced that Ken Powell will step down as Head of Arrow. The company was founded by Dr. Powell and colleagues in 1998, re-located to London from Carshalton, ...
-
AstraZeneca to divest Nordic over-the-counter portfolio
(24 Nov 2008)
AstraZeneca announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca’s strategy to focus on innovation in prescription medicines.Under the ...
Additional information
AstraZeneca PLC
London, United Kingdom
Company
|
|
|
|
|
|
Top
